Cadwalader Represents Credit Suisse in Connection With AcelRx Pharmaceuticals’ $65 Million Monetization of Expected Royalty Stream From Zalviso™

Sep 21, 2015

Cadwalader  is pleased to announce it represented Credit Suisse in a transaction for which Credit Suisse was the sole structuring and financial advisor to AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) in the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil sublingual tablet system) in the European Union by its commercial partner Grunenthal GmbH. AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that gross proceeds from the sale are $65 million.

The Cadwalader team included Christopher Cox, Corporate; Ira Schacter and Steve Lenkowsky, Capital Markets; Dorothy Auth, Intellectual Property; and David Miller, Tax.  

COVID-19 Resource Center

  • Access our insights on the impact of COVID-19 to help you navigate this unprecedented environment.

CadwaladerSpotlight

Making a Mark on Our Communities:

Pro Bono Report 2019

To assist individuals in working from home during the coronavirus social-distancing period, Cadwalader is providing clients and friends free access to our legal research platform, the Cadwalader Cabinet.